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Oral L-arginine does not improve endothelial dysfunction in risk factors such as hypertension, hypercholesterolemia,
children with chronic renal failure. hypertriglyceridemia and diabetes in this population [1].
Background. Cardiovascular disease is a major cause of However, we have previously demonstrated that conduitmortality amongst patients with chronic renal failure (CRF).
artery endothelial function is already abnormal in chil-l-arginine has been used to improve endothelial function by
dren with CRF even in the absence of these risk factors,increasing nitric oxide (NO) bioavailability and in animal mod-
els this in turn has attenuated the progression of atherosclero- suggesting a toxic effect of uremia itself [2]. Endothelial
sis. We examined whether dietary l-arginine supplementation dysfunction is a key early event that precedes the forma-
improved endothelial function in children with CRF.
tion of atherosclerotic plaques, and involves reduced bio-Methods. A randomized, double-blind, placebo-controlled,
availability of nitric oxide (NO), an important anti-ath-crossover trial of l-arginine was conducted in 21 normotensive
children aged 11.5  3 (7 to 17) years with CRF (GFR 27.4  erogenic agent [3].
13.2 mL/min/1.73 m2) in whom endothelial dysfunction had The semi-essential amino acid l-arginine is the only
previously been demonstrated. We examined the effect of l-argi- substrate for NO synthesis. Levels of l-arginine have been
nine on the endothelial response to shear stress (NO-depen-
reported as being low in CRF but this is not a universaldent) using a non-invasive technique of high-resolution ultra-
finding [4].sound. Each subject was studied before and after 4 weeks of
l-arginine (2.5 g/m2 or 5 g/m2  3/day) or placebo, separated In CRF, however, decreased clearance results in high
by a rest period of 4 weeks. Brachial artery diameter was mea- levels of circulating analogs of l-arginine, asymmetrical
sured at rest, during increased flow (endothelial-dependent di- dimethylarginine (ADMA) and its stereoisomer, sym-lation) and after 25 g of glyceryl trinitrate (endothelial-inde-
metrical dimethylarginine (SDMA) [5]. ADMA has beenpendent dilation) at each visit.
characterized as an endogenous inhibitor of NO synthaseResults. After oral l-arginine, plasma l-arginine levels rose
from 82  20 to 179  110 mol/L (P  0.001). No significant (eNOS or NOS III), the enzyme that catalyses the pro-
change in endothelial-dependent dilation during l-arginine duction of NO in vascular endothelial cells from l-argi-
(7.96  2.35 to 7.71  3.22%; P  0.05) or placebo (8.2  2.89 nine [5]. Also, NO may be inactivated by increased oxi-to 8.3  3.14%; P  0.05) was noted. There was no change in
dative stress and free radical production in CRF [7].endothelial-independent dilation.
Therefore, there are several ways in which supplementa-Conclusion. Endothelial function was not improved with
l-arginine, suggesting that dietary supplementation is not a tion with l-arginine might improve the bioavailability of
useful clinical approach in children with CRF. NO in CRF: it may correct substrate deficiency, over-
come competitive antagonism, and increase production
to overcome rapid removal. Dietary l-arginine supple-
Premature atherosclerosis is the most important cause mentation has already been shown to improve endothe-
of death in adults with chronic renal failure (CRF), and lial function in the brachial artery of young people with
is believed to be due to a high incidence of the classical hypercholesterolemia [8], and experimentally to inhibit
atherogenesis in animal models [9].
We hypothesized that arginine supplementation mayKey words: atherosclerosis, renal failure, childhood ESRD, dietary sup-
plements, uremic toxicity, nitric oxide synthesis, cardiovascular disease. improve NO bioavailability and endothelial function,
and therefore lead to a simple preventative treatmentReceived for publication October 1, 2002
strategy to decrease the risk of premature vascular dis-and in revised form May 3, 2002
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assessing the change in brachial artery diameter in re- 128/10 (Acuson), magnified using a resolution box func-
tion and gated with the R wave of the ECG. End-diastolicsponse to endothelium dependent and independent stim-
uli, in a randomized, double blind, placebo-controlled images of the vessels were acquired every 3 seconds
using data-acquisition software (Information Integrity,cross-over trial of oral l-arginine supplementation in
children with CRF. Boston, MA, USA) and stored off-line for later analysis.
Arterial diameter over a 1 to 2 cm segment was deter-
mined for each image using automatic edge detection
METHODS
software (Information Integrity). Analyses were per-
Subjects formed by an experienced vascular technician who was
blinded to the phase of the study. Using pulsed waveTwenty-five children (11 girls and 14 boys, mean age
12  3 years; range 7 to 17) with CRF [glomerular filtra- Doppler, blood flow was recorded continuously through-
out the study and was expressed as the velocity timetion rate (GFR) 50 mL/min/1.73 m2] were studied.
Twenty-four had congenital structural and one acquired integral (VTI; area under the blood velocity/time curve
for a complete cardiac cycle). Baseline recordings of ar-(neonatal cortical necrosis) causes of CRF. Exclusion
criteria were children who were smokers, hypertensive, terial diameter were made for one minute before infla-
tion of a blood pressure cuff placed distal to the sitediabetic or nephrotic or on vasoactive medication. We
did not preselect children on the basis of endothelial of arterial imaging. Recording continued for 5 minutes
during cuff inflation to 300 mm Hg and for 5 minutesfunction in order that the study group should be repre-
sentative of all children with moderate to severe CRF. after deflation. Endothelium-independent dilation of the
brachial artery was assessed by measuring the dilator re-The local research ethics committee approved the study
and informed consent was obtained from the parents or sponse to a 25 g dose of the NO donor, glyceryl trini-
trate given sublingually. This elicited vascular dilation ofguardian or from the patient in those 16 years.
the same order of magnitude as that of the endothelium-
Study design dependent flow stimulus. Results are expressed as percent-
age maximum change in vessel diameter from baseline.The trial was randomized, placebo controlled, double
blinded and cross over in design with two four-week
Laboratory assaystreatment periods separated by a four-week washout
period. Blood samples were taken following a six hour Urea, creatinine, bicarbonate and electrolytes were
measured (Vitros 750; Ortho-Clinical Diagnostics, Roch-fast. l-arginine was given at 5 g/m2 surface area to a
maximum of 7 grams three times daily. This dose was ester, NY, USA). Fasting lipid analyses were performed
for total cholesterol (TC), high-density lipoprotein (HDL)selected to provide a twofold increase in plasma l-argi-
nine levels and was based on previous studies performed and triglycerides (TGs) using colorimetric assays (Vitros
750, Ortho-Clinincal). Both very low-density lipoproteinby our group [8]. After three children with low GFR
complained of nausea and were found to have an ele- (VLDL) cholesterol and LDL were calculated. LDL sub-
fractions were measured using high-resolution polyacryl-vated urea on completion of the first treatment phase, the
dose of the treatment syrup was subsequently adjusted in amide gel electrophoresis (PAGE; Quantimetrix, Re-
dondo Beach, CA, USA) and reported as the ratio ofthose with a GFR 35 mL/min/1.73 m2 to 2.5 g/m2 three
times daily (without unblinding the study). The active less dense to more dense (LDL12:LDL345). LDL
lag times were measured by isolating LDL using densitydrug preparation and the placebo were prepared as syrup
by South Devon Healthcare (Paignton, Devon TQ4 gradient ultracentrifugation and desalted by gel filtra-
tion. Oxidation was promoted using copper; conjugated7TW, UK). Dietary intake of nitrates and nitrites were
not restricted as it was thought not to be practical in this diene production was monitored; and lag times gener-
ated [10]. Antioxidant activity was measured using aage group and we anticipated poor compliance. As each
child acted as his or her own control, it was not believed chemiluminescent assay [11]; antibodies to oxidized LDL
by enzyme linked immunosorbent assay (ELISA; Olab,to be a confounding variable. However, this places limi-
tations on the interpretation of the nitrate/nitrite data. Biomedica Gruppe, Germany); and total plasma lipid
peroxides (reaction products of oxidative damage) by a
Assessment of vascular function lipid hydroperoxide assay kit (Cayman Chemical, Ann
Arbor, MI, USA).Endothelial function was determined by recording the
dilator response of the brachial artery to increase blood Free l-arginine levels were measured by an automated
amino analyzer (Pharmacia, Milton Keynes, UK); plasmaflow generated during reactive hyperemia of the down-
stream forearm, flow mediated dilation (FMD). Subjects nitrite and nitrate (NO oxidation products) by chemilu-
minescence; nitrated proteins (nitrotyrosines: NO andlay supine in a temperature-controlled laboratory (22 to
25C). The brachial artery was scanned in longitudinal superoxide result in peroxynitrite, which combines with
tyrosine residues and is present in atherosclerotic plaques)section using a 7 MHz linear array transducer and an XP
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Table 1. Physical and biochemical characteristics at entry of mmol/L, P  0.015), a fall in bicarbonate (change in
the 21 children who completed the study
bicarbonate 	3.05  3.84 vs. 0.43  2.42 mmol/L; P 
Characteristic Mean value  SD 0.006), but no significant change in creatinine (P 0.87)
Age years 11.53 were noted. All these values returned to baseline during
Sex male:female 11:10 the washout period for those who received l-arginine first.
Height cm 142.420.9
Weight kg 40.315.8
Systolic/diastolic BP mm Hg 11314/658
GFR nr 80–120 mL/min/1.73 m2 27.413.2 Lipid analysis
Serum creatinine nr 30–102 lmol/L 258210
Baseline total cholesterols were normal but triglycer-l-arginine nr 40–120 lmol/L 7920.2
Serum total cholesterol nr 3.1–5.4 mmol/L 4.951.16 ides were elevated (Table 3). There was a significant fall
Serum triglycerides nr 0.4–1.4 mmol/L 1.50.54 in TGs on treatment versus placebo (	0.06  0.54 vs.
The normal range (nr) is given where appropriate for age-matched children. 0.19  0.57 mmol/L, P  0.005) otherwise lipid profiles
remained unchanged.
by competitive ELISA with nitrated human serum albu-
Oxidative stressmin as standard; and analogs of l-arginine, ADMA and
SDMA by high pressure liquid chromatography (HPLC). A highly significant fall in total antioxidant activity of
the serum was noted during the treatment period versus
Statistics the placebo phase (	41  30 vs. 16  54 mol/L trolox
The null hypothesis states that l-arginine will have no Eq; P  0.001; Table 3). LDL lag times (a measure of
extra effect on endothelial function over placebo. The the susceptibility of LDL to oxidation) and antibodies
study size was based on a power calculation at 80%, to oxidized LDL were above the normal range for adults
significance value of 0.05 to show a 2% improvement in at baseline and there was no significant change with
FMD. Each subject served as his or her own control. treatment. There was no effect of l-arginine on the ratio
The primary study endpoint was the change in FMD of low density to high density LDL or lipid peroxides.
(post-treatment value minus pre-treatment value) on
l-arginine and on placebo. The change on l-arginine and
placebo was compared by paired Student t tests having Nitrate chemistry
tested all data for normality using the Shapiro-Wilk and Plasma nitrate was elevated but plasma nitrite was
modified Kolmogorov-Smirnov test. Within subject vari- normal at baseline (Table 4). Plasma nitrated protein
ation in physical parameters was analyzed using repeated (nitrotyrosine) levels were increased significantly at en-
measures linear model. Baseline values before arginine try to the study when compared with data available on
or placebo and other outcome variables also were com- normal children [0.126  0.07 vs. 0.02  0.007 nitro-
pared using linear regression. Descriptive data are ex- bovine serum albumin (BSA) equivalents g/mL/mg
pressed as mean and standard deviation. protein, P  0.001). No significant changes in plasma
nitrate or nitrite were observed with l-arginine treat-
ment. Protein nitrotyrosine concentrations increasedRESULTS
with l-arginine treatment but not significantly. ThereThe clinical and biochemical characteristics of the
was no relationship between nitrotyrosine concentra-study group are shown in Table 1. Twenty-one children
tions and those of nitrate and urea. Both l-arginine ana-completed the study. One child received a renal trans-
logs ADMA and SDMA were elevated at baseline, butplant and three were unable to tolerate the l-arginine
there was no significant change on treatment or placebo.due to unpleasant taste in two and nausea in one.
A negative correlation between SDMA and GFR was
the only relationship noted with r 2  0.6 and P  0.05.
Effect of L-arginine on biochemistry Otherwise no significant relationships between NO me-
tabolites and GFR were seen.Group mean baseline levels of l-arginine were normal
and no single value was below the lower limit (Table 2).
The dose of l-arginine used produced a significant rise
Effect of oral L-arginine on vasomotor functionin serum levels during the treatment phase when dosing
There was no relationship between baseline FMD andregimen were pooled (P 0.001) compared with placebo
any clinical and biochemical parameters measured (Ta-(P  0.82). There was no significant difference in the
ble 5). There was no effect of l-arginine on baselinepost treatment levels of l-arginine on either dosing regi-
arterial diameters, baseline blood flow or reactive hyper-men. In the treatment phase versus placebo phase a rise
in urea (change in urea 3.92  4.94 vs. 0.85  2.68 emia (P  NS) on within subject analysis (hence no
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Table 2. Biochemical effect of l-arginine supplementation
Post- Change on Change on
Baseline l-arginine Baseline Post-placebo l-arginine placebo P
Urea nr 2.2–5.7 mmol/L 12.27.8 16.111.1 11.66.0 12.57.4 	3.94.9 0.92.7 0.015
Bicarbonate nr 20–26 mmol/L 223 193 222 232 	3.04 0.42.4 0.006
Creatinine nr 0–120 lmol/L 256215 270233 254210 270234 	1442 1531 NS
Data are expressed as mean  SD; nr is normal range.
Table 3. Biochemical effect of l-arginine and placebo
Post- Post- Change on Change on
Baseline l-arginine Baseline placebo l-arginine placebo P
Antibodies to
oxidized LDL
(250 mU/mL) 631501 579468 609406 562478 	2372 	4791 NS
LDL lag times
(60 min) 8719 8321 8917 8920 0.218 0.523 NS
Lipid peroxides
(mol/L) 17.321.2 16.624 13.723.2 22.934.5 	0.713.9 9.230.5 NS
Antioxidant activity
(440 mol/L
trolox Eq) 25097 20284 22690 24298 	4130 1654 0.001
Lipoprotein ratios 5.463.43 6.574.58 7.376.0 6.465.7 1.625.45 	0.97.53 NS
TC
(3.1–5.4 mmol/L) 4.81.3 4.51.1 4.91.0 4.80.9 	0.10.7 	0.20.5 NS
TG
(0.4–1.4 mmol/L) 1.53	0.53 1.450.7 1.510.55 1.960.74 	0.060.54 0.190.57 0.005
HDL
(0.91 mmol/L) 1.30.4 1.20.4 1.10.4 1.20.3 	0.010.2 0.040.24 NS
LDL
(3.3 mmol/L) 2.571.2 2.451.0 3.030.85 2.720.9 0.361.75 	0.270.62 NS
Normal values (N) are given where available. Data are expressed as mean  SD. Abbreviations are: LDL, low-density lipoprotein; TC, total cholesterol; TG,
triglycerides; HDL, high-density lipoprotein.
Table 4. Effect of l-arginine on NO chemistry
Post- Post- Change on Change on
Baseline l-arginine Baseline placebo l-arginine placebo P
Nitrates
(32.14.3 mol) 68.663.1 67.237.4 70.055.6 62.939.3 	1.1359.4 	7.1267.1 NS
Nitrites
(1.40.2 mol) 1.660.77 1.090.54 1.720.85 1.292.2 	0.570.8 	0.432.47 NS
l-argininea
(n 80–120mol/L) 82.920 179110 72.619.7 70.721.2 104110 414.5 0.001
ADMA
(0.70.1 mol/L) 1.310.55 1.190.60 0.980.48 0.840.41 	0.020.91 	0.0240.13 NS
SDMA
(0.30.1 mol/L) 2.161.41 1.881.54 1.911.37 1.901.87 	0.581.66 	0.450.93 NS
Nitrotyrosines
(0.020.007
NT-BSA equivs,
g/mL/g) 0.120.7 0.160.11 0.110.07 0.120.06 0.040.1 0.0040.05 NS
Results are expressed as mean  SD. Normal values for nitrates, nitrites, ADMA and SDMA are quoted from [2].
a Result of pooled doses
replication error), using the linear model repeated mea- the treatment phase versus the placebo phase was noted
(P  0.84; Fig. 1).sures analysis.
Flow mediated dilation: Response to GTN: Endothelial independent dilatation
Endothelial dependent dilation No significant difference in the change in response to
GTN during the treatment phase versus the placeboNo significant difference in the change in flow medi-
ated dilatation (endothelial dependent dilation) during phase was noted (P  0.2; Fig. 1).
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Table 5. Vascular responses to l-arginine and placebo
Post- Post- Change on Change on
Baseline l-arginine Baseline placebo l-arginine placebo P
Brachial artery diameter mm 3.280.62 3.280.69 3.280.63 3.240.69 0.0070.15 	0.030.18 NS
Baseline flow VTI, m 0.060.03 0.070.05 0.080.04 0.070.36 0.0040.03 0.0010.04 NS
Maximum reactive
hyperemia % 529208 471243 489333 480249 	55.2228 	8.76364 NS
FMD % 7.942.26 7.802.95 8.22.81 8.243.12 0.062.4 	0.143.23 NS
Systolic blood pressure
mm Hg 11314 10711 11215 11116 	4.26.5 111.8 NS
Diastolic blood pressure
mm Hg 6410 6110 6310 659 	3.310.4 3.315.8 NS
Data are expressed as mean  SD.
There was no significant change in resting heart rate, (2) by reducing the effect of endogenous inhibitors such
as ADMA, known to be elevated in CRF; and (3) by over-supine blood pressure during treatment or placebo phase,
coming increased oxidative inactivation. We did not dem-suggesting that there was no hemodynamic effect of the
onstrate substrate deficiency, as baseline serum l-argininel-arginine.
levels were normal. However, intracellular levels may not
correlate with serum levels in CRF, as elevated levels of
DISCUSSION oxidized LDL (which are present in CRF) are associated
Our results show that oral supplementation with l-argi- with defective cellular transport for l-arginine [19].
nine did not improve brachial artery FMD, a measure l-Arginine supplementation might overcome the ef-
of endothelial derived NO bioavailability, in children fect of elevated methylated analogs, ADMA and SDMA
with CRF, despite achieving plasma levels of twice nor- in CRF. ADMA is an inhibitor of eNOS [5] and although
mal. Indeed, it would not have been possible to increase SDMA is not a direct inhibitor, it competes with the cati-
the dose any further as the children developed a signifi- onic amino acid transporter in the endothelial cell mem-
cant increase in plasma urea, a fall in venous bicarbonate brane [20] and therefore could heighten any intracellular
and a fall in total antioxidant activity. arginine deficiency. In our children, both SDMA and
Increased cardiovascular mortality and morbidity is ADMA were elevated at baseline when compared with
well recognized in adults with CRF [1]. The adverse previously published data in children [2]. Levels were,
impact of CRF on cardiovascular mortality and morbid- however, not as high as those previously reported in
ity in the young is however even greater with a 500 adults with CRF [4, 5]. The modest elevation of ADMA
times higher rate of cardiovascular deaths than a control in our study group may have contributed to the lack of
population [12]. The initiation of vascular damage begins vascular benefit seen with l-arginine supplementation.
very early during the course of CRF, and involves the There was, however, no correlation between the response
vascular endothelium. We have previously shown im- of FMD and levels of ADMA or those of l-arginine.
paired brachial artery FMD in children with CRF from Markers of oxidative stress (antibodies to oxidized
as young as 7 years of age. Use of this non-invasive ultra- LDL, antioxidant activity) were elevated in our study.
sound technique, which is NO dependent [13, 14], en- Increased oxidative stress might be responsible for re-
ables the study of the early atherogenic process, and ducing NO bioavailability by conversion of NO to nitrate,
permits serial assessment of therapeutic interventions at nitrate, and peroxynitrite (a potent cytotoxic agent) by
a stage when maximum benefit might be expected. The superoxide. l-arginine supplementation could overcome
biological activity of NO is impaired in CRF [15], which this as in vitro studies have shown that l-arginine supple-
leads to reduced vascular relaxation, increased platelet mentations prevents preferential superoxide production
aggregation, increased leukocyte adhesion and smooth in endothelial cells exposed to near physiological levels
muscle proliferation, all processes which precede the of oxidized-LDL [21]. In our CRF children, there was
formation of atherosclerotic plaques [3]. l-Arginine is no biochemical evidence of increased NO production
the substrate for NO synthase and has been shown to (nitrate and nitrite levels remained unchanged) despite
increase endothelial function in animal models and in a doubling of the l-arginine levels. In view of the un-
clinical studies of subjects with hypercholesterolemia restricted diet this observation should be interpreted
and coronary artery disease [8, 16–18]. We postulated with caution. De Nicola et al achieved similar l-arginine
that l-arginine supplementation in children with CRF levels in adult CRF patients with oral supplementation
might increase NO bioavailability by three main mecha- and also were unable to demonstrate enhanced NO pro-
duction by measuring urinary cyclic guanosine mono-nisms: (1) by correcting a possible substrate deficiency;
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Fig. 1. Flow-mediated dilation (FMD) pre-
(left) and post- (right) treatment with L-argi-
nine (A) and placebo (B). P  NS for group
means.
phosphate (cGMP, an intracellular mediator of NO) [22]. cluding elevated urea and extracellular acidosis. These
could have affected pH dependent signaling pathwaysIt is possible that important co-factors for eNOS such as
tetrahydrobiopterin may have been deficient in our pa- and, therefore, eNOS activity. There was no correlation
between these fully reversible effects and endothelialtients [16, 23]. Under these conditions, NOS preferen-
tially reduces molecular oxygen to superoxide even in the function, however. The reduction in total antioxidant ac-
tivity of the serum suggests that increased oxidant stresspresence of adequate substrate concentrations. l-Argi-
nine at the dose used had adverse metabolic effects in- was generated during the treatment phase.
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